Cargando…

Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring

BACKGROUND: A relationship between the vaginal microbiota and tenofovir (TFV) concentrations and activity after topical administration has been previously reported. OBJECTIVE: CONRAD A15-138 was a randomized, placebo-controlled Phase I study aimed at characterizing the safety, pharmacokinetics (PK),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thurman, Andrea R., Ravel, Jacques, Gajer, Pawel, Marzinke, Mark A., Ouattara, Louise A., Jacot, Terry, Peet, M. Melissa, Clark, Meredith R., Doncel, Gustavo F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cellular and Infection Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957918/ https://www.ncbi.nlm.nih.gov/pubmed/35350436 http://dx.doi.org/10.3389/fcimb.2022.799501

Ejemplares similares

Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings
por: Thurman, Andrea Ries, et al.
Publicado: (2019)

A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir
por: Thurman, Andrea R., et al.
Publicado: (2023)

Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women
por: Thurman, Andrea Ries, et al.
Publicado: (2018)

Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study
por: Thurman, Andrea R., et al.
Publicado: (2022)

Randomized controlled phase IIa clinical trial of safety, pharmacokinetics and pharmacodynamics of tenofovir and tenofovir plus levonorgestrel releasing intravaginal rings used by women in Kenya
por: Mugo, Nelly R., et al.
Publicado: (2023)

Evaluation of Rapidly Disintegrating Vaginal Tablets of Tenofovir, Emtricitabine and Their Combination for HIV-1 Prevention
por: Clark, Meredith R., et al.
Publicado: (2014)

Genital microbiota of women using a 90 day tenofovir or tenofovir and levonorgestrel intravaginal ring in a placebo controlled randomized safety trial in Kenya
por: Dabee, Smritee, et al.
Publicado: (2022)

Genital Mucosal Drug Concentrations and anti-HIV Activity in Tenofovir-Based PrEP Products: Intravaginal Ring vs. Oral Administration
por: Ouattara, Louise A., et al.
Publicado: (2022)

Asymptomatic Bacterial Vaginosis Is Associated With Depletion of Mature Superficial Cells Shed From the Vaginal Epithelium
por: O'Hanlon, D. Elizabeth, et al.
Publicado: (2020)

Multicompartmental Pharmacokinetic Model of Tenofovir Delivery by a Vaginal Gel
por: Gao, Yajing, et al.
Publicado: (2013)

Vaginal deployment and tenofovir delivery by microbicide gels
por: Gao, Y., et al.
Publicado: (2015)

Release of Tenofovir from Carrageenan-Based Vaginal Suppositories
por: Zaveri, Toral, et al.
Publicado: (2014)

Assessing the Concordance Between Urogenital and Vaginal Microbiota: Can Urine Specimens Be Used as a Proxy for Vaginal Samples?
por: Brown, Sarah E., et al.
Publicado: (2021)

MTN-001: Randomized Pharmacokinetic Cross-Over Study Comparing Tenofovir Vaginal Gel and Oral Tablets in Vaginal Tissue and Other Compartments
por: Hendrix, Craig W., et al.
Publicado: (2013)

Composition of Vaginal Microbiota in Pregnant Women With Aerobic Vaginitis
por: Oh, Kwan Young, et al.
Publicado: (2021)

Population pharmacokinetics of tenofovir and tenofovir‐diphosphate in healthy women
por: Burns, Rebecca N., et al.
Publicado: (2015)

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
por: Kawuma, Aida N., et al.
Publicado: (2023)

Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women
por: Tanaudommongkon, Asama, et al.
Publicado: (2022)

Postbiotic gel relieves clinical symptoms of bacterial vaginitis by regulating the vaginal microbiota
por: Shen, Xin, et al.
Publicado: (2023)

A Multi-Compartment, Single and Multiple Dose Pharmacokinetic Study of the Vaginal Candidate Microbicide 1% Tenofovir Gel
por: Schwartz, Jill L., et al.
Publicado: (2011)

Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques
por: Dobard, Charles W., et al.
Publicado: (2022)

Pharmacokinetics and efficacy of topical inserts containing tenofovir alafenamide fumarate and elvitegravir administered rectally in macaques
por: Makarova, Natalia, et al.
Publicado: (2022)

Increased Dapivirine Tissue Accumulation through Vaginal Film Codelivery of Dapivirine and Tenofovir
por: Akil, Ayman, et al.
Publicado: (2014)

Rapid measures of user’s adherence to vaginal drug products using attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR) and multivariate discriminant techniques
por: Adedipe, Oluwatosin E., et al.
Publicado: (2018)

Determinants of Vaginal Microbiota Composition
por: Moosa, Yumna, et al.
Publicado: (2020)

Editorial: Vaginal dysbiosis and biofilms
por: Machado, António, et al.
Publicado: (2022)

The role of probiotics in vaginal health
por: Mei, Zhaojun, et al.
Publicado: (2022)

Altered Vaginal Microbiota Composition Correlates With Human Papillomavirus and Mucosal Immune Responses in Women With Symptomatic Cervical Ectopy
por: López-Filloy, Mariana, et al.
Publicado: (2022)

The Effect of Gender-Affirming Medical Care on the Vaginal and Neovaginal Microbiomes of Transgender and Gender-Diverse People
por: Krakowsky, Yonah, et al.
Publicado: (2022)

Dynamics of Vaginal and Rectal Microbiota Over Several Menstrual Cycles in Female Cynomolgus Macaques
por: Nugeyre, Marie-Thérèse, et al.
Publicado: (2019)

Correlation Analysis of Vaginal Microbiome Changes and Bacterial Vaginosis Plus Vulvovaginal Candidiasis Mixed Vaginitis Prognosis
por: Xiao, Bingbing, et al.
Publicado: (2022)

Mucosal effects of tenofovir 1% gel
por: Hladik, Florian, et al.
Publicado: (2015)

Potential role of tenofovir vaginal gel for reduction of risk of herpes simplex virus in females
por: Tan, DHS
Publicado: (2012)

Chitosan-Based Mucoadhesive Vaginal Tablets for Controlled Release of the Anti-HIV Drug Tenofovir
por: Cazorla-Luna, Raúl, et al.
Publicado: (2019)

298 Identifying vaginal microbiome profiles that influence tenofovir distribution in the female genital tract
por: Lantz, Alyssa M., et al.
Publicado: (2023)

Development of a Transdermal Delivery System for Tenofovir Alafenamide, a Prodrug of Tenofovir with Potent Antiviral Activity Against HIV and HBV
por: Puri, Ashana, et al.
Publicado: (2019)

The Female Vaginal Microbiome in Health and Bacterial Vaginosis
por: Chen, Xiaodi, et al.
Publicado: (2021)

Role of the vaginal microbiome in miscarriage: exploring the relationship
por: Saadaoui, Marwa, et al.
Publicado: (2023)

Editorial: Vaginal microecological disorder and gynecological diseases
por: Chen, Tingtao, et al.
Publicado: (2023)

Comparative pharmacokinetics between tenofovir disoproxil phosphate and tenofovir disoproxil fumarate in healthy subjects
por: Lee, Sangmi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_771eko54hihapdqnttvlfoh6oo